LED Medical Diagnostics Inc. ("LED" or the "Company") (TSX VENTURE:LMD)
(OTCQX:LEDIF) (FRANKFURT:LME) announced today that it has received final
approval of the TSX Venture Exchange to its previously announced and completed
non-brokered private placement of 15,000,000 units at an issue price of CDN$0.35
per unit for gross proceeds of $5.25 million. Each unit is comprised of one
common share and one common share purchase warrant with each warrant entitling
the holder to acquire one common share at an exercise price of US$0.50 for a
period of 24 months. All of the securities issued in connection with the private
placement are subject to a restricted period that expires four months after the
issuance date. 


The proceeds will be used by LED for working capital purposes, to add depth to
LED's sales and marketing team and to investigate synergistic product
opportunities in diagnostic imaging.


In connection with the private placement, LED has paid cash commissions of
CDN$388,460 and has issued 1,109,887 finder's warrants to arm's length finders.
Each finder's warrant is non-transferable and exercisable into one common share
at an exercise price of US$0.50 for a period of 24 months.


LED also announces that it has granted a total of 1,500,000 incentive stock
options to employees. Each stock option is exercisable to acquire one Common
Share of LED Medical Diagnostics at CDN$0.54 per share and the options have a
term of approximately 32 months.


About LED Medical Diagnostics Inc.

Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED
Medical Diagnostics Inc. is a leading developer of LED-based visualization
technologies for the medical industry. The Company is currently listed on the
Toronto Stock Exchange (TSX-V) under the symbol "LMD", the OTCQX under the
symbol "LEDIF", as well as the Frankfurt Stock Exchange under the symbol "LME".
For more information, visit www.ledmd.com. 


Through its wholly-owned subsidiary, LED Dental Inc., the company manufactures
the VELscope(R) Vx Enhanced Oral Assessment System, the first system in the
world to apply tissue fluorescence visualization technology to the oral cavity.
VELscope(R) Vx devices are now used to conduct more screenings for oral cancer
and other oral diseases than any other adjunctive device. To date, the VELscope
has sold over 13,000 units, and has been used to perform an estimated 25 million
exams. For more information, visit www.leddental.com.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
For media or investor relations, please contact:
Mark Komonoski, Investor Relations
(403) 255-8483/Toll-Free: (877) 255-8483
Cell: (403) 470-8384
mark.komonoski@ledmd.com/Skype: mkomonoski
www.ledmd.com
LED Medical Diagnostics (TSXV:LMD)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more LED Medical Diagnostics Charts.
LED Medical Diagnostics (TSXV:LMD)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more LED Medical Diagnostics Charts.